Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ATIC | P31939 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399875 | 0.85 | NPC1 (0.54) | RAB9ANPC1SMN1; SMN2HPGDTP53 | |
| SCHEMBL1400025 | 0.83 | NPC1 (0.57) | RAB9ANPC1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1399929 | 0.81 | NPC1 (0.62) | RAB9ANPC1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1400157 | 0.79 | NPC1 (0.61) | RAB9ANPC1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1890286 | 0.77 | RAB9A (0.57) | RAB9ANPC1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1780371 | 0.77 | RAB9A (0.55) | RAB9ANPC1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1400024 | 0.76 | NPC1 (0.64) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL1777034 | 0.76 | RAB9A (0.58) | RAB9ANPC1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1777838 | 0.75 | RAB9A (0.58) | RAB9ANPC1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1779207 | 0.75 | RAB9A (0.53) | RAB9ANPC1KDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943614-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943614-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943614-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1902047-B1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-20090111815-A1 | Carboxamide Compound and Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111815-A1 | Carboxamide Compound and Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090111815-A1 | Carboxamide Compound and Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111815-A1 | Carboxamide Compound and Use of the Same | NAA50, SIRT1, NQO2 | RAB9A 1423/4885NPC1 1353/4885KDM4E 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.